fda ruling on compounding tirzepatide The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced Thursday tirzepatide fda update FDA Clarifies

Tirzepatide weight loss typically becomes measurable in 48 weeks, with meaningful reductions by 12 weeks

Semaglutide, a drug used for weight loss and diabetes, will now be rolled out by the NHS as a heart-protective treatment for high-risk patients based on strong clinical evidence.

Is the link between GLP-1 medications and impaired vision just another case of media hysteria, or is there really something to be concerned about?

Rejuvime Medical in Metairie offers GLP-1 medical weight loss programs, hormone replacement therapy & aesthetic injectables to help you feel healthy, confident & empowered.

) for more insights and stories where curiosity changes medicine

As the semaglutide patent expiries begin in 2026 across key global markets, Indian pharma companies are racing to capture the opportunity amid rising competition, falling prices & regulatory uncertainty Ekta Bhatra breaks down who stands to gain, the risks ahead, & how GLP-1 drugs could drive the next phase of pharma growth